Immuno oncology News and Research

RSS

Experts describe role of quantitative systems pharmacology in first-in-human clinical trials

Certara, the global leader in model-informed drug development, regulatory science, market access and real-world evidence services, announced today that Clinical Pharmacology & Therapeutics has published its "Letter to the Editor" describing the important role that quantitative systems pharmacology can play in defining dosing criteria for first-in-human clinical trials, together with the European Medicines Agency's response.

26 Jul 2018

ABPI associated with NHS for 70 years in pharmaceutical research

In this special year, both the NHS and the Association of the British Pharmaceutical Industry are celebrating our respective 70th anniversaries. The histories of these two organizations have been inextricably linked since 1948 and our relationship with the NHS continues to go from strength to strength.

25 Jun 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

MD Anderson and Amgen collaborate to accelerate early-stage oncology therapies

The University of Texas MD Anderson Cancer Center and Amgen today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies.

1 Jun 2018

Alexo Therapeutics marks next significant milestone by initiating ALX148 combination cohorts

Alexo Therapeutics, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced it has initiated ALX148 combination dosing with targeted antibody therapies in its Phase 1 clinical program in patients with advanced solid tumors and lymphoma.

17 May 2018

Aravive Biologics demonstrates proof-of-mechanism for AVB-S6-500 in ongoing phase 1 study

Aravive Biologics, Inc. announced today that the company has demonstrated clinical proof-of-mechanism for AVB-S6-500 in neutralizing GAS6, based on analysis of the single ascending dose portion of the ongoing Phase 1 study.

10 May 2018

Neon Therapeutics evaluates safety, efficacy of NEO-PV-01 in combination with KEYTRUDA and chemotherapy

Neon Therapeutics, a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that it has treated the first patient in a clinical trial evaluating its proprietary personal neoantigen vaccine, NEO-PV-01, in combination with Merck's anti-PD-1 therapy, KEYTRUDA®, along with chemotherapy.

8 May 2018

Roswell Park researchers identify driver of cancer-promoting metabolic changes

Roswell Park Comprehensive Cancer Center researchers have identified a potential key player promoting cancer progression through changes in the cell environment that are conducive to metastasis.

17 Apr 2018

American Gene Technologies receives second immuno-oncology patent

American Gene Technologies International Inc., a leading gene and cell therapy company, today announced receipt of a second immuno-oncology patent on the stimulation of gamma delta T cells for treating solid tumors in epithelial cancers.

20 Mar 2018

YCC launches new Yale Center for Immuno-Oncology

Yale Cancer Center has launched the Yale Center for Immuno-Oncology. The new center will build on YCC's international leadership in immunobiology, cancer immunology, and development of novel cancer immunotherapies. It is a partnership between YCC and the department of Immunobiology at Yale University.

15 Mar 2018

Computerized tissue-imaging may help predict early recurrence of lung cancer

Case Western Reserve and Cleveland Clinic are leading development of a computerized tissue-imaging program that could soon help identify which lung cancer patients are likely to face an earlier recurrence of the disease.

20 Feb 2018

Nanobiotix receives FDA approval for first immuno-oncology trial

NANOBIOTIX, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the U.S. Food and Drug Administration has approved its Investigational New Drug Application for NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors, activated by stereotactic ablative radiotherapy (SABR) and administered in combination with an anti-PD1 antibody (nivolumab or pembrolizumab).

26 Dec 2017

Novel compound along with checkpoint inhibitors may enhance immune response in melanoma patients

A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017.

8 Dec 2017

Study finds mechanism of resistance to checkpoint inhibitors and way to reverse it

Researchers have discovered a mechanism of resistance to checkpoint inhibitors and how to reverse it. The biomarker results from the IMvigor210 study are reported at the ESMO Immuno Oncology Congress 2017.

8 Dec 2017

New first line combination therapy shows promising results in patients with advanced NSCLC

A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017.

7 Dec 2017

New intelligence tool provides clarity to scientists in booming immuno-oncology field

Hanson Wade, the London-based life sciences knowledge services specialist, has launched IO Combination Trials Intelligence (www.beacon-intelligence.com), to provide clarity to scientists and strategists in the booming immuno-oncology combination field of study.

23 Nov 2017

Philips launches proof-of-concept pilot for digital pathology services at ehi Live 2017

Royal Philips, a leader in health technology, today announced the launch of a proof-of-concept pilot for digital pathology services at a large, multi-region, scale. Announced at ehi Live, the pilot will last up to 12 months and is designed to establish ease-of-adoption for a fully integrated and digitised national pathology service, across Scottish NHS providers.

From Philips Healthcare 2 Nov 2017

Vedantra and Neon Therapeutics extend research alliance to develop impactful cancer therapies

Vedantra Pharmaceuticals, Inc., an immunotherapy company focused on developing products to treat cancer and infectious disease, and Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T-cell therapies to treat cancer, announced today that the companies have extended their non-exclusive research alliance.

31 Oct 2017

CureVac begins phase I study to assess intratumoral application of RNAdjuvant technology in patients with solid tumors

CureVac AG, a fully-integrated biotechnology company pioneering mRNA-based drugs, today announced it has initiated a Phase I study assessing the intratumoral application of its novel RNAdjuvant technology in patients with superficial solid tumors that are easily accessible for repeated intratumoral injections. RNAdjuvant is designed to amplify the scope and quality of an immune response when used alone or in combination with other immune therapies.

28 Oct 2017

Salk scientists receive $2.5 million funding to conduct pancreatic cancer clinical study

Salk Professor and HHMI Investigator Ronald Evans has been awarded $2.5 million by Stand Up 2 Cancer (SU2C) as part of a multi-institution team to conduct clinical studies to open up a new avenue for immunotherapy in the treatment of pancreatic cancer.

12 Oct 2017